Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sucrosomial magnesium is an oral **dietary supplement** formulation of magnesium in which magnesium oxide is delivered using PharmaNutra's sucrosomial technology, a phospholipid and sucrose ester-based matrix intended to protect the mineral through the gastrointestinal tract and enhance intestinal absorption. The active moiety is elemental magnesium supplied from magnesium oxide, and the product is positioned as a nutraceutical for magnesium repletion and general wellness applications such as support for muscle function, sleep, mood, cardiovascular health, bone health, and exercise performance rather than as a regulated pharmaceutical. Its mechanism is not based on a single drug-like receptor interaction; instead, it provides bioavailable magnesium, an essential mineral cofactor required for numerous enzymatic processes, neuromuscular function, and electrolyte homeostasis. Clinical literature around the formulation primarily emphasizes improved oral bioavailability and gastrointestinal tolerability versus conventional magnesium salts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sucrosomial magnesium.